WIXLIB

Amy Barton Pai, Pharm.D.11. Moore CL, *Pai AB. CKD: Pharmacotherapy in a House of Mirrors. (editorial) Adv in ChronicKidney Dis. 2010;17:381-83 PMID: 2072750712. Cardone KE, Bacchus S, Assimon M, *Pai AB, Manley HJ. Medication-Related Problems inChronic Kidney Disease. Adv in Chronic Kidney Dis 2010;17:404-412 PMID: 2072751013. Assimon M, Mousa S, Shaker O, *Pai AB. The Effect of Sevelamer Hydrochloride and CalciumBased Phosphate Binders on Mortality in Hemodialysis Patients: A Need for More Research.Consultant Pharm. 2010;35:37-51 PMID: 2021181614. *Barton Pai AB, Conner TA, McQuade CR. Therapeutic Use of the phosphate binder LanthanumCarbonate. Expert Opin Drug Metab and Toxicol 2009; 5 (1):71-81 PMID: 1923623015. *Pai AB, Conner TA. Oxidative Stress and Inflammation in Chronic Kidney Disease: Role ofIntravenous Iron and Vitamin D. J Pharm Prac 2008;21:214-22416. Pai AB. Broader Roles of Vitamin D in Patients with Chronic Kidney Disease. Kidney: A CurrentSurvey of World Literature. 2006;15:199-20117. Pai AB, Pai MP. Optimizing Antimicrobial Therapy for Gram-positive Bloodstream Infections inPatients on Hemodialysis. Adv in CKD 2006; Jul;13(3):259-70 PMID: 1681523118. Martinez I, *Pai AB. Use of antibiotic lock solutions in hemodialysis catheter-related bloodstreaminfections. Kidney: A Current Survey of World Literature. 2005;14:53-5619. *Pai AB, Smeeding JE, Brook RA. The role of sevelamer in achieving the kidney diseaseoutcome quality initiative (K/DOQI) for hyperphosphatemia. Curr Med Res Opin. 2004;20:991-999PMID: 1526524320. *Pai AB. Intravenous iron and bacteremia in hemodialysis patients. Kidney: A Current Survey ofWorld Literature. 2004;13:51-5321. *Pai AB. Warfarin for prevention of vascular access thrombosis in hemodialysis patients. Kidney:A Current Survey of World Literature. 2003;12:201-20322. *Pai AB. Iron and oxidative stress. Kidney: A Current Survey of World Literature. 2003;12:53-5623. Smith HS, Barton AE. Tizanidine in management of spasticity and musculoskeletal complaintsin the palliative care population. American Journal of Hospice and Palliative Care 2000Jan/Feb:17(1);50-58 PMID: 11094920ABSTRACTS*presenting author, !student/trainee author1.*!Raouf M, !Kelsey T, !Wilming C, Cabral K, LaFleur C, Pai AB. A student pharmacist-ledpublic health initiative for early identification of cardiovascular and kidney disease risk factors.American College of Clinical Pharmacy Global Conference, October 19, 2015, San Francisco,CA.2.*Pai AB, Narsipur S, Goldstein L. Lipoteichoic Acid As A Non-Invasive Marker Of Biofilm BurdenIn Hemodialysis (HD) Patients. National Kidney Foundation Spring Clinical Meeting. March 27,20156

Amy Barton Pai, Pharm.D.3.*Pai AB, Meyer D, Bales B, Cotero V, Pai A, Zheng N, Jiang W. Labile Iron Release FromIntravenous (IV) Iron Formulations: Considerations For Bioequivalence. National KidneyFoundation Spring Clinical Meeting. March 27, 20154.*Pai AB, Cardone K, Daoui R, Salenger P, Chen X, Kao T, Boverman G, Davenport D.Utility Of Bioelectrical Impedance Spectroscopy (BIS) With Electrical Impedance Tomography(Eit) To Evaluate Regional Volume Flux In Hemodialysis (HD) Patients. National KidneyFoundation Spring Clinical Meeting. March 27, 20155.*Pai AB, Meyer D, Bales B, Cotero V, Pai M, Zheng N, Jiang W. Performance of redox active andchelatable iron assays to determine labile iron concentrations from intravenous iron formulations.Innovation@CDER, Center for Drug Evaluation and Research, September 10, 2014, SilverSpring, MD6.Assessing Literacy and Numeracy Skills Relating to Medication Labeling in Patients on Dialysis.*!Cho S, Parker W, !Teoh B, Pai AB, Cardone KE. National Kidney Foundation Spring ClinicalMeeting. Las Vegas, NV April 23, 20147.*Pai AB, !Garba AO, Waldman J. A Non-Invasive Approach to Evaluation of Biofilm Burden inHemodialysis Patients. American Society of Nephrology Renal Week. November 6, 2013. Atlanta,GA8.!Peres de Alcantara D, *!Prokopienko AJ, Cardone K, Pai AB. Medication ManagementServices for Dialysis Patients in Brazil-A Survey of Clinicians. American College of ClinicalPharmacy, October 14, 2013, Albuquerque, NM.9.*!Prokopienko A, !Lawuyi A, Gertzberg N, Neumann P, Johnson A, Pai AB. Differential Effect ofIV Iron Compounds on Intracellular Labile Iron Pool in Aortic Coronary Endothelial Cells.American College of Clinical Pharmacology. Bethesda, MD. September 20, 2013.10. Cardone KE, Parker W, *Pai AB, Cavanaugh K. Assessment of medication label literacy andnumeracy skills in hemodialysis patients. National Kidney Foundation 2013 Spring ClinicalMeeting, April 2-6, 2013; Orlando, FL. Poster #117; Poster presentation.11. *!Patel H. !Kubotera N, !Prokopienko A. Cardone KE, Pai AB. Usage of ErythropoiesisStimulating Agents Pre and Post Bundle. American Society of Health-systems Pharmacists MidYear Clinical Meeting, December 7, 2011, New Orleans, LA12. *!Patel HV, !Prokopienko AJ, Gertzberg N, Neumann P, Johnson A, Pai AB. Differential Effectof IV Iron Compounds on Intracellular Reactive Oxygen Species (ROS) Generation in AorticCoronary Endothelial Cells. American College of Clinical Pharmacy Annual Meeting (BestStudent Paper Finalist). October 17, 2011, Pittsburgh, PA13. *Cardone KE, !Fox B, Meola S, Goldstein L, Hoy C, Salenger P, Pai AB. Effects of the ESRDMedicare Bundling Rule on Anemia Management in Private Dialysis Units. American Society ofNephrology Renal Week. November 11, 2011, Philadelphia, PA14. *Pai AB, Grabe DW, Eisele G. Effect of the Vitamin D receptor Agonist Paricalcitol on CellAdhesion Markers and ADMA in CKD 3 and 4. ERA-EDTA Annual Meeting, June 24, 2011,Prague, Czech Republic15. *!Sidile J, !Der Mesorpian P, !Makary Y, Pai AB, Haqqie S. Evaluation of Predictive Factors ofPotassium Derangement in Therapeutic Hypothermia. National Kidney Foundation, SpringClinical Meeting. April 27, 2011, Las Vegas, NV7

Amy Barton Pai, Pharm.D.16. *Pai AB, Johnson A, Role of Intravenous Iron Compounds in Pathogenesis of Pulmonary Edema.ASN Renal Week, November 17-21, 2010, Denver, CO17. *Pai AB, Johnson A. Lipoteichoic Acid (LTA) Induced Lung Endothelial Barrier Dysfunction:Possible Role of Endothelial Nitric Oxide (eNOS). ASN Renal Week, November 17-21, 2010,Denver, CO18. *Pai AB, Grabe DW, Eisele G. Effect of the Vitamin D receptor Agonist Paricalcitol on Biomarkersof Vascular Reactivity in CKD 3 and 4. ASN Renal Week, November 17-21, 2010, Denver, CO19. Johnson A, *Pai A. Lipotechoic acid (LTA) causes reactive oxygen species dependent lungendothelial barrier dysfunction. American Thoracic Society, May 17, 2010, New Orleans, LA20. *Pai AB, Gertzberg N, Neumann P, Johnson A. Role of Lipotechoic acid from Staphylococcusaureus in Pathogenesis of Pulmonary Edema. ASN Renal Week, October 30, 2009, San Diego,CA21. Conner T, Raj D, McQuade C, Olp J, *Pai AB, Effect of Intravenous Ascorbic Acid on CytokineActivation and Oxidative Stress in Hemodialysis (HD) Patients Receiving Intravenous IronSucrose (IS). ASN Renal Week, November 6, 2008, Philadelphia, PA22. *Pai AB, Raj D, !McQuade C, Olp J. !Hicks P, !Conner T. Non-transferrin Bound Iron (NTBI),Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD)Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). ASN Renal Week, November 6, 2008,Philadelphia, PA23. *Pai AB, Owen J, Clarkin M, Nielson J, Clark T. Lawler D, Kausz A. Plasma Pharmacokinetic(PK) Profile of Ferumoxytol in Healthy Subjects. Annual Meeting of the American Society ofNephrology, ASN Renal Week. November 4, 2007. San Francisco, CA24. *!Boyd A, !McQuade CR, Manley HJ, Pai AB. Correlation between the Renal Quality of LifeProfile (RQLP) and Short Form 36 (SF 36) in a United States (US) Hemodialysis (HD)Population. Abstract SU PO1099. Annual Meeting of the American Society of Nephrology, ASNRenal Week. November 4, 2007. San Francisco, CA25. *!Demirovic J, Pai AB, Conner TC, Pai M. Comparison of Nafcillin and Cefazolin for MethicillinSensitive Staphylococcus aureus (MSSA) Related Bloodstream Infections (BSI) in Hemodialysis(HD) Patients. Annual Meeting of the American Society of Nephrology, ASN Renal Week.November 4, 2007. San Francisco, CA26. *!McQuade CR, !Boyd AV, !Conner T, Pai AB. Clinical pharmacy research training program(CPRTP): a longitudinal approach to career development. Abstract # 268. Annual Meeting of theAmerican College of Clinical Pharmacy. October 16, 2007. Denver, CO27. *Pai AB, Norenberg JP, !Boyd AV, Raj DSC, MD, Chan L, Intravenous Iron is Associated withIncreased Cytochrome P-450 3A4 (CYP3A4) Activity in Hemodialysis (HD) Patients J Am SocNephrol 2006;17:481A28. *!Horton E, Pai AB, Anselmo L, Garcia D. Case-control analysis of prophylactic enoxaparintherapy in obese patients. American College of Clinical Pharmacy, October 28, 2006 St. Louis,MO29. *!McQuade C, !Boyd A, !Chavez A, !Burke R, Pai AB. Factors associated with hypocalcemiain hemodialysis patients receiving cinacalcet HCL for secondary hyperparathyroidism. AmericanCollege of Clinical Pharmacy, October 29, 2006 St. Louis, MO8

Amy Barton Pai, Pharm.D.30. *Pai AB, !Depczynski JC, !Martinez I, !Boyd A, !Chavez A, Manley HJ. Impact of ClinicalPharmacy Services on Medication Costs, Hospitalization Rates and Drug-Related Problems inHemodialysis (HD) Patients. J Am Soc Nephrol 2005;16:725A31. *Pai AB, Pai M, Raj DSC. Hemodialysis Clearance of Amino Acids (AA) during IntradialyticSupplementation. J Am Soc Nephrol 2005;16:717A32. *Pai AB, !Adeniyi O, Osman F, Shah V, Ferrando A, Raj DSC. Amino Acid and Protein Kineticsin ESRD Patients with Type-2 Diabetes Mellitus. J Am Soc Nephrol 2005;16:714A33. *Osman F, !Adeniyi O, Varghese E, Shah V, Waters D, Pai AB, Ferrando A, Raj DSC. AminoAcid Infusion Does Not Decrease Protein Catabolism during Hemodialysis. J Am Soc Nephrol2005;16:48A34. *Pai AB, Pai M, !Depczynski JC, !McQuade C, Mercier RC. Effect of Non-Transferrin BoundIron on Staphylococcus aureus Growth in Hemodialysis Patients Receiving Intravenous IronSucrose. J Am Soc Nephrol 2005;16:453A35. *Pai AB, !Boyd A, !Chavez A, Manley HJ. Assessment of quality of life in hemodialysis patientsreceiving pharmaceutical care. Pharmacotherapy 2005;25:146636. *Pai AB, Harford A, !Boyd A, !McQuade C, Zager P. Comparison of Oxidative Stress Markers inHemodialysis (HD) Patients Receiving Iron Dextran (ID), Sodium Ferric Gluconate (SFG) and IronSucrose (IS). Pharmacotherapy 2005;25:151337. *!Martinez I, Pai AB. Frequency of Hyperkalemia in Hemodialysis Patients on AngiotensinConverting Enzyme Inhibitors (ACE-I) and Angiotensin Receptor Blocker Therapy. AmericanCollege of Clinical Pharmacy, Spring Meeting, April 12, 2005, Myrtle Beach, SC.38. *!Calhoun W, Pai A, Morgan M, Pickett G, Shah V, Raj D. Skeletal Muscle Is an ImportantSource of Interleukin-6 and Oxidative Stress in End-Stage Renal Disease (ESRD) J Am SocNephrol 2004;SAPO79039. *!Depczynski JC, Pai AB, Boyd A, Manley HJ. A Randomized Study to Determine the Impact ofClinical Pharmacy Services on Medication Costs, Hospitalization Rates and Quality of Life inHemodialysis Patients. American Society of Helath-Systems Pharmacists Mid-year meeting.December 11, 2003. New Orleans, LA40. *Harford A, Stidley C, Hunt C, Paine S, Pai AB, Scavini M. Brown R, Zager P. Iron Dose andSurvival in Hemodialysis Patients. J Am Soc Nephrol 2003:14;26641. *!Boyd A, Pai AB, Townsend K, Tinklenberg A, Spalding CT. Optimal Sampling for InternationalNormalized Ratios in Hemodialysis Patients with Central Venous Catheters. J Am Soc Nephrol2003:14;729A42. *Stidely CS, Sun Y, Harford A, Brown R, Pai AB, Zager PG. Increased mortality in hemodialysispatients receiving no iron and high dose iron therapy. Abstract # 554358 World Congress ofNephrology, Berlin, Germany. June 8-12 200343. *Pai AB, Brown R, Spalding CT, Zager P. Clotting events within target INR ranges inhemodialysis patients treated with warfarin. (Abstract # F-PO826) J Am Soc Nephrol2002:13;229A44. *Pai AB, Lin S, Arruda J, Lau A. Long-term therapeutic effects of paricalcitol in hemodialysispatients. (Abstract # A0304) J Am Soc Nephrol 2000:11;56A9

Amy Barton Pai, Pharm.D.45. *Pai AB, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters inhemodialysis patients. (Abstract # 153) American College of Clinical Pharmacy Annual MeetingLos Angeles, CA November, 200046. *Pai AB, Lin S, Lau AH. Evaluating Long-term therapy with paricalcitol in hemodialysis patients.(Abstract # 190) American College of Clinical Pharmacy Spring Practice and Research Forum,Monterey, CA April 200047. *Lin S, Pai AB, Lau AH. Correlation of patient variables to abnormal lipid profiles in thehemodialysis population. (Abstract # 189) American College of Clinical Pharmacy Spring Practiceand Research Forum, Monterey, CA April 200048. *Barton AB, Carson J, Lombardi TP. Evaluating Diuretic Resistance and Implementation ofthTherapeutic Substitution; Torsemide for Bumetanide. (Abstract #150) 16 Annual Conference forPharmacy Residents and Preceptors, Baltimore, MD May 1997OTHER PUBLICATIONS1.Wilkerson T, Pai AB. Optimizing Pharmacotherapy in Chronic Kidney Disease– The Role of theClinical Pharmacist. Pharmacist Quarterly, Phoenix Indian Medical Center. March 20072.Ault A. Preventing ESRD Drug Interactions. Internal Medicine News. January 15, 2006. (pressrelease based on abstract presented at American Society of Nephrology Meeting, November2005)3.Pai AB. Summary of Recent Studies of Dual Blockade of the Renin-Angiotensin-AldosteroneSystem with ACE-inhibitors(ACEI) and Angiotensin Receptor Blockers(ARB) in Diabetic KidneyDisease. American College of Clinical Pharmacy Nephrology PRN Newsletter. July 20054.Martinez I, Pai AB. Antibiotic Lock Solutions for Hemodialysis Catheter-related BloodstreamInfections. American College of Clinical Pharmacy Nephrology PRN Newsletter. March 20055.Koertner B, Pai AB, Impact of National Kidney Foundation Kidney Disease Outcome QualityInitiative Guidelines on Treatment of Renal Osteodystrophy in Hemodialysis Patients. AmericanCollege of Clinical Pharmacy Nephrology PRN Newsletter. March 20046.Ponto JA, Pai AB (guest editor).Radiopharmaceuticals and Dialysis. Correspondence ContinuingEducation Courses for Nuclear Pharmacists and Nuclear Medicine Professionals. 2002;10(1):1377.Pai AB. Lead in Calcium Supplements. American College of Clinical Pharmacy Nephrology PRNNewsletter. September 20028. Barton AB, Carson J. The clinical use of loop diuretics in congestive heart failure and chronicrenal insufficiency. Therapeutic Forum-St. Peter’s Hospital, October 1996BOOK CHAPTERS1.Pai AB. Iron Oxide Nanoparticles for Treatment of Anemia of Chronic Kidney Disease: Too Muchof a Good Thing? R. Bawa (Editor), G. F. Audette and B. E. Reese. (Assistant Editors): Handbookof Clinical Nanomedicine: Law, Business, Regulation, Safety and Risk, Pan Stanford Publishing,Singapore (2015) [ISBN 978-981-4669-22-1]10

Amy Barton Pai, Pharm.D.2.Pai AB. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy APathophysiologic Approach, Ninth edition, DiPiro J et al eds. Mcgraw Hill. 20133.Pai AB. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy APathophysiologic Approach, Eighth edition, DiPiro J et al eds. Mcgraw Hill. 20104.Pai AB, Mason DL. Acute Kidney Diseases. in Tisdale J, Miller D. Drug-Induced Diseases,ndPrevention, Detection and Management. 2 edition, 2010 American Society of Health-systemsPharmacists. Bethesda, MD.5.Pai AB, Pai MP. Acute Renal Diseases. in Tisdale J, Miller D. Drug-Induced Diseases,Prevention, Detection and Management. 2005 American Society of Health-systems Pharmacists.Bethesda, MD.6.Pai AB, Rohrschieb M. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy APathophysiologic Approach, Seventh edition, DiPiro J et al eds. Mcgraw Hill. 20087.Pai AB, Conner TC. Chronic Kidney Disease in Applied Therapeutics: The Clinical Use of Drugs.th9 Edition, Koda-Kimble et al eds. Lipincott Williams and Wilkins. 2008GRANTS AWARDED2014A pilot study of monitoring hydration level in hemodialysis patients with multi-channel electricalimpedance tomography. General Electric Global Research Cardone KE (PI), Pai AB (Co-PI), 25,0002013An in vitro-in vivo correlation model to predict serum non-transferrin bound iron from intravenousiron compounds. NIH 1U01FD004889, Pai AB (PI) Pai MP, Meyer D, Bales, B (Co-Is), 499,9992011Use of a simple immunoassay to quantitatively assess catheter biofilm to predict systemicinflammatory burden and catheter-related bloodstream risk. Dialysis Clinic Inc. Paul TeschanResearch Fund. Pai AB (PI). Mousa S (Co-I), Waldman J (Co-I), Harford A (Co-I), 100,0002008Development of a Pilot Chronic Kidney Disease Biomarker Surveillance Cohort: The AlbanyPharmacy Biosurveillance (Alpha-Bios) Cohort Study. Scholarship of Discovery, Pai AB (PI),Mason DL, (Co-PI), Grabe DW, Pallotta K, Cheng M (Co-Is), 6,000Effects of 19-nor-1α-dihydroxyvitamin D2 (paricalcitol) versus placebo on oxidative stress andvascular reactivity in CKD patients. Abbott Laboratories. Pai AB (PI), Grabe D, Mason DL EiseleG (Co-Is), 108,0002006Effect of Intravenous Ascorbic Acid on Oxidative Stress and Cytokine Activation in HemodialysisPatients on Intravenous Iron. Pai AB (PI), Conner TA Co-I, Raj DSC, Co-I University of NewMexico General Clinical Research Center, 6,982Cytokine Activation and Oxidative Stress in Hemodialysis Patients Receiving IV Iron. AmericanCollege of Clinical Pharmacy and University of New Mexico General Clinical Research Center,Pai AB (PI), Raj DSC (Co-I), 23,500Cytokine Activation, Oxidative Stress and Mitochondrial Toxicity Associated with IV Iron Use inPatients on Hemodialysis. Clinical Translational Science Center Pilot Project RFA. Pai AB (PI)Raj DSC, Walker MK, Shah VO. (Co-Is) 50,00011

Amy Barton Pai, Pharm.D.2005Accuracy of creatinine clearance equations in morbidly obese patients: Influence of central bodyfat distribution. University of New Mexico General Clinical Research Center Pai MP (PI), Pai AB(Co-I), Demirovic J (Co-I), 3,080.2004Effects of Intravenous Iron Sucrose on the Rate of Staphylococcus aureus Growth in UremicSerum. University of New Mexico Resource Allocation (RAC) Grant. Pai AB (PI), MP Pai (Co-I),Mercier RC (Co-I), Depczynski JC (Co-I) 10,0002003Comparison of Markers of Oxidative Stress in Hemodialysis Patients Receiving Iron Dextran,Sodium Ferric Gluconate and Iron Sucrose. American College of Clinical Pharmacy AnemiaResearch Award and University of New Mexico General Clinical Research Center, Pai AB (PI),Zager P (Co-I), Zager R, (Co-I), Norenberg JP (Co-I), 20,9462002Impact of Clinical Pharmacy Services on Medication Cost and Hospitalization Rates inHemodialysis Patients. Health Outcomes Research Starter Grant, PhRMA Foundation, (2 years)Pai AB (PI), HJ Manley (Co

August 2001-June 2007 Assistant Professor of Pharmacy and Nephrology . University of New Mexico . College of Pharmacy and School of Medicine Albuquerque, New Mexico . EDUCATION. 2015-present Arizona State University . Master of Healthcare Innovation . 1997-1999 Albany College of Pharmacy, Albany, New York . Doctor of Pharmacy, magna cum laude